<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1147">
  <stage>Registered</stage>
  <submitdate>1/05/2006</submitdate>
  <approvaldate>1/05/2006</approvaldate>
  <nctid>NCT00320346</nctid>
  <trial_identification>
    <studytitle>Phase II Study of Pandemic Influenza Vaccine</studytitle>
    <scientifictitle>A Double-Blind, Randomised, Multi-Centre Study to Evaluate the Safety, Tolerability, Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limited's Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population (=18 Years to =64 Years of Age).</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CSLCT-PAN-05-18</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Pandemic Influenza Vaccine

Other interventions: Pandemic Influenza Vaccine


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and Immunogenicity</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Lot to Lot Consistency</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy Adults</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>64</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Previous vaccination with an influenza Vaccine containing the H5N1 strain

          -  History of clinically significant medical conditions

          -  History of Guillian-Barre Syndrome or active Neurological disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>CMAX, a division of IDT Australia - Adelaide</hospital>
    <hospital>Murdoch Childrens Research Institute - Melbourne</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode> - Adelaide</postcode>
    <postcode>3052 - Melbourne</postcode>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Seqirus</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The World Health Organisation has warned that an influenza pandemic is inevitable. The avian
      influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic.
      This study will test the safety and immunogenicity of a H5N1 Pandemic Influenza Vaccine in
      healthy adults. The Study will also assess Lot to Lot consistency of the Pandemic Influenza
      Vaccine.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00320346</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Richmond, Dr</name>
      <address>Princess Margaret Hospital for Children</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>